BioCryst Pharmaceuticals Inc (NAS:BCRX)
$ 7.82 -0.37 (-4.52%) Market Cap: 1.62 Bil Enterprise Value: 2.18 Bil PE Ratio: 0 PB Ratio: 0 GF Score: 75/100

Q4 2023 BioCryst Pharmaceuticals Inc Earnings Call Transcript

Feb 26, 2024 / 01:30PM GMT
Release Date Price: $5.79 (+1.40%)
Operator

Good day and welcome to the BioCryst fourth-quarter 2023 earnings conference call. (Operator Instructions) Please note, this event is being recorded. I would now like to turn the conference over to John Bluth at BioCryst. Please go ahead.

John Bluth
BioCryst Pharmaceuticals Inc - Chief Communications Officer

Thank you very much. Good morning, and welcome to BioCryst fourth-quarter and yearend 2023 corporate update and financial results conference call. Today's press release and accompanying slides are available on our website. Participating with me today are CEO, Jon Stonehouse; CFO, Anthony Doyle; Chief Commercial Officer, Charlie Gayer; Chief Medical Officer, Dr. Ryan Arnold. Following our remarks, we'll answer your questions.

Before we begin, please note that today's conference call will contain forward-looking statements, including the statements regarding future results unaudited and forward-looking financial information as well as the company's future performance and or achievements. These statements are subject to known and unknown risks and

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot